PEDIATRICS Vol. 48 No. 2 August 1971, pp. 318-322
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feigin, R. D.
Right arrow Articles by Haymond, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feigin, R. D.
Right arrow Articles by Haymond, M. W.

Floxuridine Treatment of Congenital Cytomegalic Inclusion Disease

Ralph D. Feigin M.D.1, Penelope G. Shackelford M.D.1, Darryl C. Devivo M.D.1, and Morey W. Haymond M.D.1

1 Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, 660 S. Kingshighway St. Louis, Missouri 63110

A patient with culturally confirmed congenital cytomegalic inclusion disease was treated at 12 days of age with Floxuridine (FUDR). FUDR was intravenously administered in a dose of 0.5 mg/kg/day as a single continuous 12-hour infusion each day for 5 consecutive days. Positive cultures for cytomegalovirus were obtained from urine and saliva throughout the course of therapy as well as from cerebrospinal fluid and a hip joint effusion at the conclusion of therapy. No therapeutic effect of FUDR was demonstrable clinically and no toxic drug effects were noted.